8-K: H.B. Fuller Adds Medical Tech Expert to Board

H.B. Fuller Company announced the appointment of R. Jeffrey Bailly to its Board of Directors, effective September 23, 2026, bringing extensive experience in medical technologies and corporate transformation.

Summary

• H.B. Fuller Company has appointed R. Jeffrey Bailly to its Board of Directors, effective September 23, 2026.
• Mr. Bailly's appointment follows the resignation of Ruth S. Kimmelshue from the Board, effective immediately.
• Mr. Bailly brings over three decades of executive leadership experience, particularly in business transformation, M&A, manufacturing, and medical technology.
• He previously served as CEO of UFP Technologies, Inc. from 1995 to 2026, during which the company grew significantly and expanded into higher-growth medical end markets.
• Mr. Bailly has been appointed to serve on the Audit Committee and the Compensation Committee of H.B. Fuller's Board.
• H.B. Fuller aims to leverage Mr. Bailly's expertise to support its repositioning towards faster-growing, higher-margin end markets and achieve over 20% adjusted EBITDA margin.
• Mr. Bailly will receive an annual cash retainer of $100,000, an initial grant of 1,300 restricted stock units, and is eligible for an annual discretionary grant of deferred phantom stock units valued at $165,000.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strategic board refreshment and alignment with future growth objectives.

Positives

• Appointment of R. Jeffrey Bailly to the Board of Directors brings significant executive leadership experience, especially in medical technology and corporate transformation.
• Mr. Bailly's background aligns with H.B. Fuller's strategic priority to focus on higher-growth, higher-margin end markets.
• The company expects to benefit from Mr. Bailly's expertise in M&A and manufacturing excellence to drive growth and shareholder value.
• Mr. Bailly's tenure at UFP Technologies saw substantial revenue and profitability growth, with a significant increase in share price over his final five years as CEO.
• The company is actively seeking to enhance its board with individuals whose expertise directly supports its strategic objectives.

Negatives

• Ruth S. Kimmelshue has resigned from the Board of Directors, though her departure is not due to any disagreements.
• The filing does not contain any financial results or performance metrics, focusing solely on board changes.

Risks

• The company's strategic repositioning towards higher-growth, higher-margin end markets may face execution challenges.
• Integration of new capabilities and technologies to support market shifts could be complex.
• Reliance on M&A for growth introduces inherent risks associated with deal execution and integration.

Future Outlook

The company aims to leverage Mr. Bailly's expertise to accelerate its path to greater than 20% adjusted EBITDA margin and drive toward long-term financial objectives by sharpening its portfolio and investing in attractive growth opportunities.

Management Comments

• "Jeff brings highly relevant operating and leadership experience across key medical end markets as we focus on accelerating our path to greater than 20% adjusted EBITDA margin," said Celeste Mastin, President and CEO of H.B. Fuller.
• "He has led a global business through periods of meaningful transformation and growth, and his perspective will be highly valuable as we continue to sharpen our portfolio, invest in attractive growth opportunities, and drive toward our long-term financial objectives."
• "I am excited to be joining H.B. Fullers Board at this important inflection point in the Companys evolution," said R. Jeffrey Bailly.
• "I have dedicated most of my career to scaling advanced manufacturing businesses by matching innovative technologies with specific market needs. Through this work, I have seen the substantial benefits of reorienting portfolios towards strategically aligned, high growth end markets, such as medical. I look forward to working with the Board and management team to continue advancing H.B. Fullers evolution and creating durable value for shareholders."
• "On behalf of the entire Board, I would like to thank Ruth for all her contributions over the past 9 years," said Terry Rasmussen, Chair of H.B. Fullers Board.
• "As we move into this next phase of H.B. Fullers transformation, our Board and leadership team have been closely engaging with shareholders to ensure a clear understanding of their views. In those discussions, we have been recommended several impressive Board candidates, and we are please to bring on a director whose background aligns perfectly with our strategic priorities. We look forward to immediately benefitting from the wealth of perspective and expertise that Jeff brings to the table."
• "It has been an honor to serve on H.B. Fuller's Board for nearly a decade," said Ruth Kimmelshue.
• "I take this step with great confidence in the leadership team's strategy, and I'm pleased that Jeff's experience will help carry that momentum forward."

Industry Context

StockSavvy.ai notes that H.B. Fuller's strategic focus on higher-growth, higher-margin medical end markets aligns with a broader industry trend of specialty chemical companies seeking to diversify into more resilient and profitable sectors, often through targeted acquisitions and portfolio adjustments.

Management Changes

Corporate Governance

Related Party Transactions

• There are no transactions between Mr. Bailly and the Company that would be reportable under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders may benefit from the addition of a director with a proven track record of driving shareholder value and aligning company strategy with profitable growth.
• The strategic shift towards higher-margin markets could lead to improved financial performance, potentially benefiting all stakeholders.
• Board refreshment signals a commitment to strategic evolution, which can be viewed positively by investors.

Next Steps

• R. Jeffrey Bailly will serve on the Audit Committee and the Compensation Committee of the Board.
• The company will continue to sharpen its portfolio and invest in attractive growth opportunities.
• The company aims to accelerate its path to greater than 20% adjusted EBITDA margin.

Key Dates

Recommendation

The filing reports a board change and strategic alignment, but lacks financial performance data or forward-looking guidance that would typically drive a stronger recommendation. The addition of an experienced director is positive, but it's a governance-focused update rather than a performance-driven event.

Keywords

Board of Directors, Director Appointment, Medical Technology, Corporate Governance, Executive Leadership, M&A, Manufacturing, Strategic Repositioning